Telemedicine Consultation and Supervision Fees: Buying Genetic-Test Orders and Supposed Oversight

A telemedicine network paid practitioners for genetic-test orders tied to at least $89,137,434 in Medicare payments, according to a New Jersey criminal information. The alleged scheme put a price on both the prescription and its supposed supervision. Medicare paid for the testing at the other end.

The telemedicine guilty plea on September 24, 2020 covered conspiracies involving kickbacks, health care fraud and wire fraud, according to the Justice Department’s account. The criminal information describes how the payments worked.

Two Payments Bought Different Things

The criminal information described approximately $20 per test order and $2 for purported supervision. One payment compensated the practitioner producing the order. The other compensated the supervisory role. The alleged arrangement treated clinical oversight as something to buy alongside the prescription. Medicare bore the cost of the tests those orders produced.

Calling both payments consulting fees loses the distinction. An insider who handled the payments could know which role each recipient filled and what work the company treated as completed.

What did the supposed supervisor actually do for the orders carrying that supervision? Someone handling those payments may know whether the fee followed a review or simply followed the order.

The Order Was the Product

Telemedicine can supply the order that another business uses to bill Medicare. In its July 20, 2022 Special Fraud Alert, the HHS Office of Inspector General described companies recruiting patients and practitioners, supplying information for reviews, paying for signatures or reviews, and transferring the resulting orders to downstream buyers.

The company pays the practitioner, and the laboratory bills Medicare. The patient’s test order connects those businesses. Looking only at whether a practitioner billed a remote visit misses the business buying the practitioner’s output.

A staffing or payment employee may understand how the orders were financed before a laboratory submitted its claim. Their view of the business starts with who was paid to produce the order, rather than with the claim that eventually reached Medicare.

A Consultation Label With a Prescription Trigger

The criminal information alleged that a prescription could earn payment even without a consultation. A contract and a payment ledger answer different questions. We connect payment terms to the orders and the work performed, because a familiar label can obscure the transaction an employee sees every day.

The same distinction carries through to supervision. A payment described as oversight calls for an account of the oversight. Who reviewed the clinical work, what they reviewed and how their involvement affected an order are different questions from whose name appeared in a supervisory arrangement.

The work a practitioner understood themselves to be doing and the representations attached to their orders may tell different stories. For the employee handling payments, the corresponding distinction is between paying for that work and paying for an output.

Genetic-Test Orders Are Supposed to Serve Patient Care

Medicare’s general diagnostic-test rule connects the order to a treating professional who uses the results to manage the patient’s medical problem. The signature carries a clinical purpose: the test is meant to inform care.

That makes the patient’s relationship with the ordering professional and the use of the results central to understanding a genetic-test arrangement. The consultation is supposed to support a medical decision. The result is supposed to go back into the patient’s care. Those are the clinical events behind the paperwork a laboratory receives.

The consultation and supervision payments in the criminal information invite that comparison between the service described and the work performed. A separate civil genetic-testing case shows what the disconnect can look like inside a portal. In a Delaware civil case, the government’s complaint alleged that a physician’s approval through MySpecialistMD generated signed laboratory-billing documents despite failed patient contact.

What Is a Red Flag for Health Care Fraud?

Compensation tied to order volume, insufficient patient contact and missing follow-up are among the suspect features the Inspector General identified in its telemedicine alert. Its warning also addressed recruited beneficiaries and businesses confined to a single product or product class.

Those features give an insider a way to describe what they are seeing. A business can control which patients enter, what information reaches a clinician, which product the encounter can produce and what earns a payment. Understanding those choices together explains more than the word consultation on an invoice.

What Evidence Is Needed to Prove Fraud?

We work with insiders to assess consultation and supervision payments and build the case with healthcare fraud whistleblower lawyers. That includes understanding where the actual encounter differs from what the order says happened. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

An accounts employee may recognize the event that released a payment. A practitioner may know what patient information was available and what the signed form said. A supervisor may know whether the promised review took place. Those perspectives concern different parts of the same transaction.

You Know What Made the Fee Payable

If you handled consultation payments, signed genetic-test orders or supplied the supposed supervision, speak with our whistleblower experts about what the business actually paid for. We build your strongest telemedicine whistleblower case around the payment terms, clinical work and claims, bring in healthcare fraud whistleblower lawyers who understand order schemes, and stay beside you through the case.